Gene: FAM162A

26355
C3orf28|E2IG5|HGTD-P
family with sequence similarity 162 member A
protein-coding
3q21.1
Ensembl:ENSG00000114023 MIM:608017 Vega:OTTHUMG00000159494 UniprotKB:Q96A26
NC_000003.12
PubMed|SNP Mapped
1   ANCO-SNPs
AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.516e-1 (AD)  2.995e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs2002594chr3:122392714 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
DNAJC190.922
COPS80.922
EMC40.919
FH0.919
NDUFB50.919
OCIAD10.918
GHITM0.914
MRPS360.914
RAB2A0.912
COX7B0.912

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.729
OR4F29-0.684
MTRNR2L6-0.386
MTRNR2L9-0.369
MTRNR2L10-0.341
MTRNR2L8-0.329
MTRNR2L2-0.326
CSAG1-0.325
SIX1-0.303
MAGEA12-0.295

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0512461-methylanthracene[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FAM162A mRNA28329830
C0194992-nitrofluorene2-nitrofluorene results in increased expression of FAM162A mRNA15890375
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA"27188386
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of FAM162A mRNA15890375
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of FAM162A mRNA29067470
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of FAM162A gene27153756
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of FAM162A mRNA15890375
D000643Ammonium ChlorideAmmonium Chloride affects the expression of FAM162A mRNA16483693
D001280AtrazineAtrazine results in decreased expression of FAM162A mRNA27614199
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of FAM162A mRNA19770486|2373587
C543008bis(4-hydroxyphenyl)sulfone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of FAM162A mRNA28628672
C006780bisphenol Abisphenol A affects the expression of FAM162A mRNA25181051
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FAM162A mRNA28628672
C584509C646 compoundC646 compound results in decreased expression of FAM162A mRNA26191083
D019256Cadmium ChlorideCadmium Chloride results in increased expression of FAM162A mRNA25596134
D002211CapsaicinCapsaicin results in decreased expression of FAM162A mRNA16278290
D002220CarbamazepineCarbamazepine affects the expression of FAM162A mRNA25979313
C004656chloroacetaldehydechloroacetaldehyde affects the expression of FAM162A mRNA25596134
C074702chromium hexavalent ionchromium hexavalent ion affects the expression of FAM162A mRNA28472532
C059262cidofovircidofovir results in decreased expression of FAM162A mRNA25596134
D004002Clodronic AcidClodronic Acid results in decreased expression of FAM162A mRNA25596134
C018021cobaltous chloridecobaltous chloride results in increased expression of FAM162A mRNA24612858
C018021cobaltous chloridecobaltous chloride results in increased expression of FAM162A mRNA22202117
C018021cobaltous chloridezinc chloride inhibits the reaction [cobaltous chloride results in increased expression of FAM162A mRNA]22202117
D016572CyclosporineCyclosporine results in decreased expression of FAM162A mRNA20106945|2163298
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of FAM162A mRNA]27941970
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of FAM162A mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FAM162A mRNA28628672
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of FAM162A mRNA17361019
D002945CisplatinCisplatin results in decreased expression of FAM162A mRNA25596134
D002945CisplatinCisplatin results in increased expression of FAM162A mRNA27392435
C000944dicrotophosdicrotophos results in decreased expression of FAM162A mRNA28302478
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of FAM162A mRNA15890375
D004128DimethylnitrosamineDimethylnitrosamine results in increased expression of FAM162A mRNA15890375
D004317DoxorubicinDoxorubicin affects the expression of FAM162A protein29385562
C118739entinostatentinostat results in increased expression of FAM162A mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA"27188386
C045651epigallocatechin gallateepigallocatechin gallate results in decreased expression of FAM162A mRNA22079256
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FAM162A mRNA22079256
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in decreased expression of FAM162A mRNA23649840
C007738fluoranthene[1-methylanthracene co-treated with fluoranthene] results in decreased expression of FAM162A mRNA28329830
C039281furanfuran results in decreased expression of FAM162A mRNA25539665
D006830Hydralazine[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM162A mRNA17183730
C492448ICG 001ICG 001 results in decreased expression of FAM162A mRNA26191083
D007069IfosfamideIfosfamide results in decreased expression of FAM162A mRNA25596134
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of FAM162A mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FAM162A mRNA28628672
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] affects the expression of FAM162A mRNA25613284
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of FAM162A mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of FAM162A mRNA28628672
C410337K 7174K 7174 results in decreased expression of FAM162A mRNA24086573
D058185Magnetite Nanoparticles[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of FAM162A mRNA26378955
D008701MethapyrileneMethapyrilene results in increased expression of FAM162A mRNA15890375
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of FAM162A mRNA23103053
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of FAM162A mRNA23179753|2718838
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of FAM162A mRNA26011545
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of FAM162A mRNA23649840
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in decreased expression of FAM162A mRNA22776087
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in decreased expression of FAM162A protein22776087
C500085muraglitazarmuraglitazar results in increased expression of FAM162A mRNA21515302
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of FAM162A mRNA"25620056
C029938nickel sulfatenickel sulfate results in decreased expression of FAM162A mRNA22714537
C029938nickel sulfatenickel sulfate results in increased expression of FAM162A mRNA17382205
C002741N-nitrosomorpholineN-nitrosomorpholine results in increased expression of FAM162A mRNA19716841
D010100OxygenOxygen deficiency results in increased expression of FAM162A mRNA24236059|2559613
D010100OxygenOxygen deficiency results in increased expression of FAM162A mRNA20880076
D010416PentachlorophenolPentachlorophenol results in increased expression of FAM162A mRNA23892564
C023036perfluorooctanoic acidperfluorooctanoic acid results in decreased expression of FAM162A mRNA27614199
D010882Piperonyl ButoxidePiperonyl Butoxide results in increased expression of FAM162A mRNA15890375
C006253pirinixic acidpirinixic acid results in decreased expression of FAM162A mRNA15890375
D010936Plant ExtractsPlant Extracts results in increased expression of FAM162A mRNA23557933
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of FAM162A mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in increased expression of FAM162A mRNA22079256
D011374ProgesteroneProgesterone results in decreased expression of FAM162A mRNA23018184
D011794QuercetinQuercetin results in decreased expression of FAM162A mRNA21632981
C089730rosiglitazonerosiglitazone results in increased expression of FAM162A mRNA21515302
D004113Succimer[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of FAM162A mRNA26378955
C501413tesaglitazartesaglitazar results in increased expression of FAM162A mRNA21515302
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FAM162A mRNA21570461|2468072
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of FAM162A mRNA15667827
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] affects the expression of FAM162A mRNA25613284
D013849ThimerosalThimerosal results in decreased expression of FAM162A mRNA27188386
C066340tolcaponetolcapone binds to FAM162A protein19783845
D014212TretinoinTretinoin results in decreased expression of FAM162A mRNA23724009
C011559tributyltintributyltin results in decreased expression of FAM162A mRNA27614199
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of FAM162A mRNA24935251|2627250
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of FAM162A mRNA"26179874
D014635Valproic Acid[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM162A mRNA17183730
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of FAM162A mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of FAM162A mRNA23179753
D014635Valproic AcidValproic Acid results in increased expression of FAM162A mRNA23179753|2438349
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of FAM162A gene25560391
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162A mRNA"27188386
D015032ZincZinc deficiency results in increased expression of FAM162A mRNA20857495
C016837zinc chloridezinc chloride inhibits the reaction [cobaltous chloride results in increased expression of FAM162A mRNA]22202117

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI15082785  16698020  
GO ID GO Term Qualifier Evidence PubMed
GO:0006919activation of cysteine-type endopeptidase activity involved in apoptotic process-IDA15082785  
GO:0043065positive regulation of apoptotic process-IDA15082785  
GO:0051402neuron apoptotic process-IEA-  
GO:0071456cellular response to hypoxia-IDA15082785  
GO:0090200positive regulation of release of cytochrome c from mitochondria-IDA15082785  
GO ID GO Term Qualifier Evidence PubMed
GO:0005739mitochondrion-IDA-  
GO:0005829cytosol-IDA-  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28990359Ancestry-specific and sex-specific risk alleles identified in a genome-wide gene-by-alcohol dependence interaction study of risky sexual behaviors. (2017 Dec)Polimanti RAm J Med Genet B Neuropsychiatr Genet